Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07217223

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies. Treatment will be delivered over a 2-week period with daily weekday treatments i.e., five tDCS sessions, each lasting 20 minutes, spaced by approximately 20-minute inter-session intervals, for a total of three hours a day. Participants will self-administer treatment at home under direct remote supervision. Pre- and post- treatment neurophysiological biomarkers sessions will also be carried out. The study aims to examine changes in mood, brain activity, and related clinical outcomes before, during, and after treatment, with the goal to provide more information that can be used for future studies.

PLEASE NOTE: THERE WILL BE 4 APPOINTMENTS THAT MUST OCCUR IN PERSON IN SAN DIEGO, CA.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People between the ages of 18 and 85 at the time of screening.
  • Currently diagnosed with Major Depressive Disorder (MDD) as measured by the MINI and a MADRS score of ≥ 20.
  • Safe for TMS as measures by the TMS Adult Safety Screening (TASS).
  • Medical records confirming a history of failing to achieve clinical response to an adequate antidepressant trial as defined an Antidepressant Treatment History Form (ATHF) score ≥ 3 or ) or shown intolerance to at least two inadequate trials (score 1 or 2), without psychiatric illness due to a general medical condition.
  • Stable internet connection and a device compatible with Microsoft Teams.

Exclusion criteria

  • History of psychotic or bipolar disorder or depression with psychotic features;
  • Significant borderline personality disorder;
  • Significant comorbid obsessive-compulsive or post-traumatic stress:
  • Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal;
  • Clinically significant suicidality disorder;
  • Chronic depression (defined as of over 5 years duration);
  • Pregnancy or lactation, lack of adequate birth control in women of childbearing age;
  • History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent symptoms;
  • Unstable medical illness;
  • Contraindication to receiving tDCS (e.g., ferromagnetic implant, history of seizure, known brain lesion);
  • History of TMS (greater than 15 sessions) without a clinically meaningful response.; History of ketamine (greater than 4 sessions) without a clinically meaningful response;
  • Require a benzodiazepine with a dose > lorazepam 2 mg/day;
  • dermatological conditions contraindicating tDCS;
  • Non-correctable sensory impairments;
  • Inability to consent or participate as an outpatient

Treatment and study plan

Spaced Transcranial Direct Current Stimulation (tDCS)

Device

tDCS will be self-administered at home under the supervision of a trained clinical research coordinator using the Soterix Medical mini-CT device with remote monitoring via a secure videoconferencing platform (e.g., Microsoft Teams).The device is designed for safe, remote tDCS delivery. Participants will be treated using a stimulation at 2 mA, with a 30-second ramp-up and ramp-down phase.

Primary outcomes

  1. Feasibility (Recruitment)

    Time frame: From baseline clinical assessment prior to treatment to 12 weeks after last treatment.

    Recruitment rate will be measured as the number of patients enrolled by the conclusion of the study, reported as a whole number.

  2. Feasibility (Retention)

    Time frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.

    Retention rate will be measured as the percentage of enrolled patients who complete all study visits, reported as a percentage.

  3. Feasibility (Adherence)

    Time frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.

    The proportion of completed sessions relative to the total prescribed sessions, expressed as a percentage.

  4. Safety of at-home spaced tDCS

    Time frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.

    Safety will be measured by the number of serious adverse events (SAEs)

  5. Tolerability to spaced tDCS

    Time frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.

    Tolerability will be measured by the number of adverse events (AEs).

Secondary outcomes

  1. Changes from pre-treatment depressive symptomatology in post-treatment

    Time frame: From baseline clinical assessment prior to treatment, to 12 weeks after last treatment.

    Changes in depressive symptoms will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), which ranges from 0 to 60, with higher scores indicating more severe depression. A decrease in the MADRS score will be interpreted as an improvement in symptoms.

  2. Biomarker Discovery: Short-Interval Intracortical Inhibition (SICI) via TMS-EMG

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    TMS-EMG will be used to evaluate changes in SICI.

  3. Biomarker Discovery: Intracortical Facilitation (ICF) via TMS-EMG

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    TMS-EMG will be used to evaluate changes in intracortical facilitation

  4. Biomarker Discovery: Cortical Silent Period (CSP) via Transcranial Magnetic Stimulation-Electromyography (TMS-EMG)

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    TMS-EMG will be used to assess changes in the cortical silent period (CSP).

    Unit of Measurement: Duration (milliseconds).

  5. Biomarker Discovery: TMS-Evoked Potential (TEP) Component Amplitudes via TMS-EEG

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    TMS-EEG will be used to evaluate changes in TMS-evoked potential (TEP) component amplitudes.

    Unit of Measurement: Voltage (µV).

  6. Biomarker Discovery: Resting-State Electroencephalography (rsEEG)

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    rsEEG will be used to analyze changes in brain activity patterns at rest.

    Unit of Measurement: Frequency (Hz)

  7. Biomarker Discovery: Resting-State Electroencephalography (rsEEG)

    Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 12 weeks after last treatment.

    rsEEG will be used to analyze changes in brain activity patterns at rest.

    Unit of Measurement: Amplitude (µV).

Study contacts

Contact information is provided by the study sponsor or research team.

Interventional Psychiatry

CONTACT

[email protected]

858-966-5832

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Oct 15, 2025
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.